Boston Scien Cp SEC Filings

Boston Scientific director Cheryl Pegus reported an equity award in the form of deferred stock units. On March 2, 2026, she acquired 24 deferred stock units at a stated price of $0.00 per unit, reflecting $1,845.25 of compensation based on the common stock’s closing price that day.

Each deferred stock unit represents a commitment by Boston Scientific to issue one share of common stock in the future. These units were granted in lieu of 50% of her yearly cash compensation, vest in full at the next annual stockholder meeting, and the underlying shares will be delivered after she leaves the Board under the company’s non-employee director deferred compensation plan. Following this grant, her reported direct holdings total 5,917 deferred stock units.

Morano Susan E reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director Susan E. Morano received an equity grant of 24 shares of common stock on March 2, 2026, at no cash cost to her. The award is restricted stock granted in lieu of 50% of her cash compensation, valued at $1,845.25 based on the closing share price on the grant date, and will vest in full at the next annual meeting of stockholders. Following this grant, she directly holds 6,663 Boston Scientific shares.

Boston Scientific director Christophe Pierre Weber reported receiving two restricted stock grants as a non-employee director. He acquired 556 shares of common stock as an initial equity award with an approximate value of $42,419.50, prorated under the company’s non-employee director compensation program.

Weber also received 323 restricted shares in lieu of 100% of his prorated yearly cash retainer, with an approximate value of $24,662.50. Both grants were based on the closing stock price on the grant date and are scheduled to vest in full at the company’s 2026 annual meeting of stockholders.

Boston Scientific director Cathy R. Smith received two grants of deferred stock units as part of her non-employee director compensation. She acquired 556 deferred stock units valued at approximately $42,419.50 as an equity award and 323 deferred stock units valued at approximately $24,662.50 in lieu of yearly cash compensation. Each deferred stock unit represents a commitment to issue one share of common stock. Both grants are prorated from her appointment date to the 2026 annual meeting and vest in full at the next annual meeting, with shares delivered after she leaves Board service under the company’s deferred compensation plan.

Boston Scientific (BSX) senior vice president Emily Woodworth reported equity compensation activity involving restricted stock units and common stock. On March 1, 2026, she exercised or converted 838 restricted stock units, which represent a commitment to issue one share of common stock for each unit.

The same day, she acquired 838 shares of Boston Scientific common stock through this derivative exercise. Also on March 1, 372 shares of common stock were disposed of at $76.85 per share in a transaction classified as payment of tax liability by delivering securities. After these transactions, she directly owned 1,676 restricted stock units and 2,859 common shares.

Boston Scientific discussed the strategic rationale and integration approach for its proposed acquisition of Penumbra during a TD Cowen conference Q&A on March 3, 2026. Executives said Penumbra would operate as a stand-alone global business unit within Boston Scientific’s cardiovascular/ICTx portfolio, retaining its commercial team and leadership. Management highlighted opportunities to scale Penumbra outside the U.S., leverage Boston Scientific’s supply chain (including Costa Rica manufacturing), and cross-sell complementary products across neurovascular, thrombectomy, vascular and interventional cardiology accounts. The transaction remains subject to regulatory review and customary closing conditions; Boston Scientific referenced a Form S-4/proxy filing in connection with the proposed transaction.

Boston Scientific executive Arthur C. Butcher reported a discretionary rebalancing transaction in the company’s 401(k) plan involving 6,851 shares of common stock at $75.76 per share. This was an indirect transaction under the company’s 401(k) Retirement Savings Plan, treated as a discretionary transaction under Rule 16b-3(f).

Following this plan-related activity, his indirect 401(k) holdings were 20,205 shares of Boston Scientific common stock, and his directly held position was 55,792 shares. The filing reflects a retirement-plan allocation decision rather than a traditional open-market purchase or sale.

Boston Scientific (BSX) agreed to acquire Penumbra in a cash-and-stock merger under an Agreement and Plan of Merger dated January 14, 2026. At the Effective Time, each issued Penumbra share (other than excluded shares) will convert into the right to receive either $374.00 in cash or 3.8721 Boston Scientific shares, subject to the proration provisions of the Merger Agreement.

The Merger Agreement fixes the aggregate allocation at 73.26% of Penumbra shares to receive cash and 26.74% to receive stock (rounded to whole shares). Penumbra stockholders may elect cash, stock or a mix; elections are subject to proration and no fractional Boston Scientific shares will be issued. The Merger requires Penumbra stockholder approval at a special meeting and customary regulatory clearances.

Boston Scientific arranged new bank financing to support its planned acquisition of Penumbra and refresh its liquidity facilities. The company entered into a $3.0 billion multi-year revolving credit agreement maturing on February 26, 2031, with interest tied to its credit rating and a required maximum leverage ratio.

It also put in place a $2.0 billion 364-day revolving credit facility and a $6.0 billion delayed draw term loan agreement, split into two 364-day tranches that can be drawn at the Penumbra acquisition closing. Tranche B borrowings must later be repaid or refinanced with proceeds from future equity or debt offerings, and both the revolvers and term loans carry ticking fees on undrawn commitments.

Following these new agreements, Boston Scientific terminated its prior revolving credit facility originally dated May 10, 2021, consolidating its bank financing under the new 2026 credit agreements.